纳米聚合物激活了PAR2基因编辑,以抑制瘤转移
Yuhong Jiang1, Yuke Li2, Dongmei Zheng3
1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
Biomaterials
|January 12, 2025
概括
这项研究介绍了NanoPt@Cas9-PAR2,这是一种新的纳米粒子系统,用于传递CRISPR/Cas9到目标PAR2. 这种方法有效地抑制癌症转移,并降低基化疗毒性.
科学领域:
- 在瘤学瘤学.
- 纳米技术纳米技术
- 基因编辑 基因编辑
背景情况:
- 癌症转移是死亡的主要原因,常常由化疗加剧.
- 蛋白酶激活受体2 (PAR2) 在促进癌细胞迁移和转移方面发挥着关键作用.
- 克里斯普尔/卡斯9基因编辑为抑制转移提供了潜在的策略,但有效的传递仍然是一个挑战.
研究的目的:
- 开发一种基于纳米粒子的CRISPR/Cas9传递系统,以向PAR2并抑制癌症转移.
- 评估该系统在减少转移和化疗诱导的毒性方面的疗效,在体外和体内.
主要方法:
- 纳米化聚合 (NanoPt) 被用作CRISPR/Cas9.9的药物载体.
- 该NanoPt@Cas9-PAR2系统的设计是为了提供CRISPR/Cas9用于PAR2基因编辑.
- 进行了体外和体内研究,以评估抗转移效应和毒性.
主要成果:
- 与传统治疗相比,纳米Pt@Cas9-PAR2显著增强了抗转移效应.
- 该系统有效地减轻了与基化疗相关的全身毒性.
- 由NanoPt@Cas9-PAR2通过RAGE/ERK信号传导诱导的PAR2缺陷减弱的上皮-介质细胞过渡 (EMT) 和铁亡,抑制癌细胞迁移.
结论:
- 纳米Pt@Cas9-PAR2代表了一种安全有效的综合策略,用于癌症治疗.
- 这种方法减轻了PAR2信号,减少了细胞毒性,提供了一个有前途的治疗途径.
- 通过纳米颗粒传递的CRISPR/Cas9针对PAR2显示出克服转移和治疗耐药性的潜力.
关键词:
通过CRISPR/Cas9进行交付.铁化是铁化的一种.转移 转移 转移 转移聚合物金聚合物金蛋白酶激活受体2 (PAR2) 是一种蛋白质酶激活受体.在 RAGE/ERK 信号中使用 RAGE/ERK 信号更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
5.9K
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
28.2K
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K